Ranolazine

Found 5 Sample Hits

m/z	Adducts	Species	Organ	Scanning	Sample
427.2758	[M-H2O+NH4]+ PPM:12.7	Homo sapiens	colorectal adenocarcinoma	DESI ()	439TopL, 409TopR, 429BottomL, 419BottomR-profile - MTBLS415 Resolution: 17μm, 157x136 Description The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024).
410.2409	[M+H-H2O]+ PPM:7.1	Homo sapiens	esophagus	DESI ()	TO31T - MTBLS385 Resolution: 75μm, 56x54 Description
445.2732	[M+NH4]+ PPM:17.3	Homo sapiens	esophagus	DESI ()	LNTO22_1_7 - MTBLS385 Resolution: 75μm, 69x54 Description
445.2732	[M+NH4]+ PPM:17.3	Homo sapiens	esophagus	DESI ()	LNTO22_2_1 - MTBLS385 Resolution: 75μm, 89x88 Description
445.2737	[M+NH4]+ PPM:16.2	Homo sapiens	esophagus	DESI ()	LNTO22_2_2 - MTBLS385 Resolution: 75μm, 135x94 Description

Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker